JP2017512786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017512786A5 JP2017512786A5 JP2016558347A JP2016558347A JP2017512786A5 JP 2017512786 A5 JP2017512786 A5 JP 2017512786A5 JP 2016558347 A JP2016558347 A JP 2016558347A JP 2016558347 A JP2016558347 A JP 2016558347A JP 2017512786 A5 JP2017512786 A5 JP 2017512786A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- trifluoromethyl
- benzamide
- fluoro
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 pyrazolopyrimidinyl Chemical group 0.000 claims 53
- 125000000217 alkyl group Chemical group 0.000 claims 29
- 125000000623 heterocyclic group Chemical group 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000002431 hydrogen Chemical group 0.000 claims 17
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 15
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 10
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims 9
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000003226 pyrazolyl group Chemical group 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 4
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims 4
- 229940053128 nerve growth factor Drugs 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- PAMCRRDMORMCSM-UHFFFAOYSA-N n-(trifluoromethyl)benzamide Chemical compound FC(F)(F)NC(=O)C1=CC=CC=C1 PAMCRRDMORMCSM-UHFFFAOYSA-N 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- MPVRBTDECKCFEY-UHFFFAOYSA-N CC(N)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=C1)C1=CC=CC=C1 Chemical compound CC(N)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=C1)C1=CC=CC=C1 MPVRBTDECKCFEY-UHFFFAOYSA-N 0.000 claims 2
- 208000016192 Demyelinating disease Diseases 0.000 claims 2
- 206010012305 Demyelination Diseases 0.000 claims 2
- 206010067601 Dysmyelination Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 101150111783 NTRK1 gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- XUZRZKLRCQZFRE-UHFFFAOYSA-N 2-fluoro-4-methyl-N-[6-[2-(methylamino)-2-oxoethyl]-2-phenylindazol-3-yl]-5-pyrimidin-2-ylbenzamide Chemical compound CNC(=O)Cc1ccc2c(NC(=O)c3cc(c(C)cc3F)-c3ncccn3)n(nc2c1)-c1ccccc1 XUZRZKLRCQZFRE-UHFFFAOYSA-N 0.000 claims 1
- ITZLPHSULOBASY-UHFFFAOYSA-N 2-fluoro-N-[5-(hydroxymethyl)-2-phenylpyrazolo[4,3-b]pyridin-3-yl]-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide Chemical compound OCC1=NC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 ITZLPHSULOBASY-UHFFFAOYSA-N 0.000 claims 1
- ZJANXHIOPJZRFG-UHFFFAOYSA-N C(#N)C1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O Chemical compound C(#N)C1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O ZJANXHIOPJZRFG-UHFFFAOYSA-N 0.000 claims 1
- RVPFEMHDILVAKN-UHFFFAOYSA-N C(C)(=O)NCC=1C=C(C=CC1)N1N=C2C(N=CC=C2)=C1NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O Chemical compound C(C)(=O)NCC=1C=C(C=CC1)N1N=C2C(N=CC=C2)=C1NC(C1=C(C=C(C(=C1)C1=NC=CC=N1)C(F)(F)F)F)=O RVPFEMHDILVAKN-UHFFFAOYSA-N 0.000 claims 1
- CSIQWYJANFGMGW-UHFFFAOYSA-N C1(=CC=CC=C1)N1N=C2C(N=CC(=C2)C(=O)N)=C1NC(=O)C1=CC(=C(C=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound C1(=CC=CC=C1)N1N=C2C(N=CC(=C2)C(=O)N)=C1NC(=O)C1=CC(=C(C=C1)C(F)(F)F)C1=NC=CC=N1 CSIQWYJANFGMGW-UHFFFAOYSA-N 0.000 claims 1
- WYGHKVWQCCSHOV-UHFFFAOYSA-N CC(O)C1=CC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 WYGHKVWQCCSHOV-UHFFFAOYSA-N 0.000 claims 1
- MDANURKSLYFPRZ-UHFFFAOYSA-N CC(O)C1=CC2=C(NC(=O)C3=CC=C(C(=C3)C3=NN(C)C=C3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=C(NC(=O)C3=CC=C(C(=C3)C3=NN(C)C=C3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 MDANURKSLYFPRZ-UHFFFAOYSA-N 0.000 claims 1
- LLVGDVKKDXMYDS-UHFFFAOYSA-N CC(O)C1=CC2=NN(C(NC(=O)C3=C(Cl)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=NN(C(NC(=O)C3=C(Cl)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=C1)C1=CC=CC=C1 LLVGDVKKDXMYDS-UHFFFAOYSA-N 0.000 claims 1
- FHQGBHLHSCXWTJ-UHFFFAOYSA-N CC(O)C1=CC2=NN(C(NC(=O)C3=C(Cl)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2N=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=NN(C(NC(=O)C3=C(Cl)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2N=C1)C1=CC=CC=C1 FHQGBHLHSCXWTJ-UHFFFAOYSA-N 0.000 claims 1
- KFUMLBPRQSNFIS-UHFFFAOYSA-N CC(O)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=N1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)=C2C=N1)C1=CC=CC=C1 KFUMLBPRQSNFIS-UHFFFAOYSA-N 0.000 claims 1
- CDGQZCLRDVGCPS-UHFFFAOYSA-N CC(O)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NN(C)C=C3)C(F)(F)F)=C2N=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=CC2=NN(C(NC(=O)C3=C(F)C=C(C(=C3)C3=NN(C)C=C3)C(F)(F)F)=C2N=C1)C1=CC=CC=C1 CDGQZCLRDVGCPS-UHFFFAOYSA-N 0.000 claims 1
- OHTZNYGIBTVDIF-UHFFFAOYSA-N CC(O)C1=NC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 Chemical compound CC(O)C1=NC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 OHTZNYGIBTVDIF-UHFFFAOYSA-N 0.000 claims 1
- BBERDCONFQXSPX-UHFFFAOYSA-N CN(C)CC1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O Chemical compound CN(C)CC1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O BBERDCONFQXSPX-UHFFFAOYSA-N 0.000 claims 1
- VXAVCZZIGYUMSQ-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 Chemical compound CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 VXAVCZZIGYUMSQ-UHFFFAOYSA-N 0.000 claims 1
- ZCNGBXMCQVZBFM-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)N)C1=CC=CC=C1 Chemical compound CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)N)C1=CC=CC=C1 ZCNGBXMCQVZBFM-UHFFFAOYSA-N 0.000 claims 1
- AXFSAIJYBOTAFJ-UHFFFAOYSA-N CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C=CC(=CC12)C(=O)N)C1=CC=CC=C1 Chemical compound CN1N=C(C=C1)C=1C=C(C=CC1C(F)(F)F)C(=O)NC=1N(N=C2C=CC(=CC12)C(=O)N)C1=CC=CC=C1 AXFSAIJYBOTAFJ-UHFFFAOYSA-N 0.000 claims 1
- NRBMTQFGYWJGBX-UHFFFAOYSA-N ClC1=C(C(=O)NC=2N(N=C3C=2N=C(C=C3)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound ClC1=C(C(=O)NC=2N(N=C3C=2N=C(C=C3)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 NRBMTQFGYWJGBX-UHFFFAOYSA-N 0.000 claims 1
- LNPFNUJPXPEIBG-UHFFFAOYSA-N ClC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(C)(C)O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound ClC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(C)(C)O)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 LNPFNUJPXPEIBG-UHFFFAOYSA-N 0.000 claims 1
- BVMGHNSPKPYMDY-UHFFFAOYSA-N ClC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound ClC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 BVMGHNSPKPYMDY-UHFFFAOYSA-N 0.000 claims 1
- HNMGFURPOCLUBZ-UHFFFAOYSA-N ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=1N=CC(=C2)C(=O)N)C1=CC=CC=C1 Chemical compound ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=1N=CC(=C2)C(=O)N)C1=CC=CC=C1 HNMGFURPOCLUBZ-UHFFFAOYSA-N 0.000 claims 1
- GBNVSNXLEIWGNC-UHFFFAOYSA-N ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=CC=CC=C1 Chemical compound ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=CC=CC=C1 GBNVSNXLEIWGNC-UHFFFAOYSA-N 0.000 claims 1
- VMRBTIOELUXXOS-UHFFFAOYSA-N ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)NCCO)C1=CC=CC=C1 Chemical compound ClC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)NCCO)C1=CC=CC=C1 VMRBTIOELUXXOS-UHFFFAOYSA-N 0.000 claims 1
- ODJPBHRPHYLZGR-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C2N=CC(=C3)C(C)(C)O)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NNC=C1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C2N=CC(=C3)C(C)(C)O)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NNC=C1 ODJPBHRPHYLZGR-UHFFFAOYSA-N 0.000 claims 1
- IWURPFDWEVICJW-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=2C=NC(=C3)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=2C=NC(=C3)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 IWURPFDWEVICJW-UHFFFAOYSA-N 0.000 claims 1
- KUVFCTFHZSUVLM-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=2N=CC(=C3)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=2N=CC(=C3)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 KUVFCTFHZSUVLM-UHFFFAOYSA-N 0.000 claims 1
- JQEZBHLEXLABRF-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(=O)N)C2=C(C=CC=C2)C)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(=O)N)C2=C(C=CC=C2)C)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C JQEZBHLEXLABRF-UHFFFAOYSA-N 0.000 claims 1
- NDIAMNTZKTYHGQ-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C NDIAMNTZKTYHGQ-UHFFFAOYSA-N 0.000 claims 1
- DIJLWKUDISEUSD-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CNCCO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CNCCO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C DIJLWKUDISEUSD-UHFFFAOYSA-N 0.000 claims 1
- NCSKJOFRPAWSMQ-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 NCSKJOFRPAWSMQ-UHFFFAOYSA-N 0.000 claims 1
- KUWWQOJJZDEENF-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NNC=C1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NNC=C1 KUWWQOJJZDEENF-UHFFFAOYSA-N 0.000 claims 1
- ASVQVVFLEKIMIE-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=C(C=CC=23)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=C(C=CC=23)C(=O)N)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 ASVQVVFLEKIMIE-UHFFFAOYSA-N 0.000 claims 1
- PVWWJVBOYHULJD-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=CC(=CC23)CCO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=CC(=CC23)CCO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 PVWWJVBOYHULJD-UHFFFAOYSA-N 0.000 claims 1
- DPFLQQUIFVLOJF-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=CC(=CC=23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=CC(=CC=23)CO)C2=CC=CC=C2)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 DPFLQQUIFVLOJF-UHFFFAOYSA-N 0.000 claims 1
- KXECLFFOKKSMQT-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=CC(=CC=23)CO)C2=NNC(=C2)C)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3C=CC(=CC=23)CO)C2=NNC(=C2)C)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 KXECLFFOKKSMQT-UHFFFAOYSA-N 0.000 claims 1
- AADZKIQXCDCINB-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3C=NC(=CC32)CO)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C Chemical compound FC1=C(C(=O)NC=2N(N=C3C=NC(=CC32)CO)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C AADZKIQXCDCINB-UHFFFAOYSA-N 0.000 claims 1
- NIJMADWXVFTQKO-UHFFFAOYSA-N FC1=C(C(=O)NC=2N(N=C3N=CC(=CC32)C(C)(C)O)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 Chemical compound FC1=C(C(=O)NC=2N(N=C3N=CC(=CC32)C(C)(C)O)C3=CC=CC=C3)C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1 NIJMADWXVFTQKO-UHFFFAOYSA-N 0.000 claims 1
- APOONGNZUGSHGT-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 APOONGNZUGSHGT-UHFFFAOYSA-N 0.000 claims 1
- VJJNXINELPSTKN-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=C1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=CC=CC=C1 VJJNXINELPSTKN-UHFFFAOYSA-N 0.000 claims 1
- DSHCMFAIYUYYRV-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C(=CC=CC12)C(=O)N)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C(=CC=CC12)C(=O)N)C1=CC=CC=C1 DSHCMFAIYUYYRV-UHFFFAOYSA-N 0.000 claims 1
- QSBXBHUEPYNQTB-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C1N=C(C=C2)C(=O)N)C2=CC=CC=C2 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C1N=C(C=C2)C(=O)N)C2=CC=CC=C2 QSBXBHUEPYNQTB-UHFFFAOYSA-N 0.000 claims 1
- ZYJJNZCNBOVLCR-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=C(C=CC=C2)C Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=C(C=CC=C2)C ZYJJNZCNBOVLCR-UHFFFAOYSA-N 0.000 claims 1
- HYSMHBHSBGHVHB-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=C(C=CC=C1)C Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)N)C1=C(C=CC=C1)C HYSMHBHSBGHVHB-UHFFFAOYSA-N 0.000 claims 1
- YAOPRVSKJLEMOO-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)NCCO)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NC=CC=N1)C(=O)NC=1N(N=C2C=C(C=CC=12)C(=O)NCCO)C1=CC=CC=C1 YAOPRVSKJLEMOO-UHFFFAOYSA-N 0.000 claims 1
- VETNEPBRBSGTPG-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NN(C=C1)C)C(=O)NC=1N(N=C2C1N=CC(=C2)C(=O)N)C2=CC=CC=C2 VETNEPBRBSGTPG-UHFFFAOYSA-N 0.000 claims 1
- VVZWYJXHLGUKAL-UHFFFAOYSA-N FC1=C(C=C(C(=C1)C(F)(F)F)C1=NNC=C1)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)N)C1=CC=CC=C1 Chemical compound FC1=C(C=C(C(=C1)C(F)(F)F)C1=NNC=C1)C(=O)NC=1N(N=C2C=C(C=CC12)C(=O)N)C1=CC=CC=C1 VVZWYJXHLGUKAL-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- FKUSMPPXJLOXCR-UHFFFAOYSA-N N-[5-(2,2-difluoro-1-hydroxyethyl)-2-phenylindazol-3-yl]-2-fluoro-5-pyrimidin-2-yl-4-(trifluoromethyl)benzamide Chemical compound OC(C(F)F)C1=CC2=C(NC(=O)C3=C(F)C=C(C(=C3)C3=NC=CC=N3)C(F)(F)F)N(N=C2C=C1)C1=CC=CC=C1 FKUSMPPXJLOXCR-UHFFFAOYSA-N 0.000 claims 1
- YLIPQRCSRJTFHZ-UHFFFAOYSA-N N-[6-(2-amino-2-oxoethyl)-2-phenylpyrazolo[4,3-b]pyridin-3-yl]-2-chloro-4-methyl-5-pyrimidin-2-ylbenzamide Chemical compound CC1=CC(Cl)=C(C=C1C1=NC=CC=N1)C(=O)NC1=C2N=CC(CC(N)=O)=CC2=NN1C1=CC=CC=C1 YLIPQRCSRJTFHZ-UHFFFAOYSA-N 0.000 claims 1
- HSZLGMGLKICUOQ-UHFFFAOYSA-N NCC=1C=CC2=C(N(N=C2C1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NN(C=C1)C)C(F)(F)F)F)=O Chemical compound NCC=1C=CC2=C(N(N=C2C1)C1=CC=CC=C1)NC(C1=C(C=C(C(=C1)C1=NN(C=C1)C)C(F)(F)F)F)=O HSZLGMGLKICUOQ-UHFFFAOYSA-N 0.000 claims 1
- GXHGCXDPSFWOQQ-UHFFFAOYSA-N O=C1N(C(CN1)=O)CC=1C=2C(N=CC1)=C(N(N2)C2=CC=CC=C2)NC(C2=C(C=C(C(=C2)C2=NN(C=C2)C)C(F)(F)F)F)=O Chemical compound O=C1N(C(CN1)=O)CC=1C=2C(N=CC1)=C(N(N2)C2=CC=CC=C2)NC(C2=C(C=C(C(=C2)C2=NN(C=C2)C)C(F)(F)F)F)=O GXHGCXDPSFWOQQ-UHFFFAOYSA-N 0.000 claims 1
- KGAQXHWMFVCAJX-UHFFFAOYSA-N OC(C(F)F)c1ccc2c(NC(=O)c3cc(-c4ncccn4)c(cc3F)C(F)(F)F)n(nc2c1)-c1ccccc1 Chemical compound OC(C(F)F)c1ccc2c(NC(=O)c3cc(-c4ncccn4)c(cc3F)C(F)(F)F)n(nc2c1)-c1ccccc1 KGAQXHWMFVCAJX-UHFFFAOYSA-N 0.000 claims 1
- ZFLNPQMSUGXZTP-UHFFFAOYSA-N OC(C)(C)C1=CC=2C(N=C1)=C(N(N2)C2=CC=CC=C2)NC(C2=CC(=C(C=C2)C(F)(F)F)C2=NN(C=C2)C)=O Chemical compound OC(C)(C)C1=CC=2C(N=C1)=C(N(N2)C2=CC=CC=C2)NC(C2=CC(=C(C=C2)C(F)(F)F)C2=NN(C=C2)C)=O ZFLNPQMSUGXZTP-UHFFFAOYSA-N 0.000 claims 1
- UFPNZOKJIKFUGS-UHFFFAOYSA-N OC1(CC1)C1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O Chemical compound OC1(CC1)C1=CC2=C(N(N=C2C=C1)C1=CC=CC=C1)NC(C1=CC(=C(C=C1)C(F)(F)F)C1=NN(C=C1)C)=O UFPNZOKJIKFUGS-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2014/074143 WO2015143652A1 (en) | 2014-03-26 | 2014-03-26 | TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF |
| CNPCT/CN2014/074143 | 2014-03-26 | ||
| PCT/US2015/021952 WO2015148354A2 (en) | 2014-03-26 | 2015-03-23 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017512786A JP2017512786A (ja) | 2017-05-25 |
| JP2017512786A5 true JP2017512786A5 (enExample) | 2018-05-10 |
Family
ID=54193893
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558339A Pending JP2017508766A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
| JP2016558347A Pending JP2017512786A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558339A Pending JP2017508766A (ja) | 2014-03-26 | 2015-03-23 | ＴｒｋＡキナーゼ阻害薬、その組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9862716B2 (enExample) |
| EP (2) | EP3122345B1 (enExample) |
| JP (2) | JP2017508766A (enExample) |
| KR (2) | KR20160132114A (enExample) |
| CN (2) | CN106456582A (enExample) |
| AU (2) | AU2015236438A1 (enExample) |
| CA (2) | CA2942817A1 (enExample) |
| MX (2) | MX2016012483A (enExample) |
| RU (2) | RU2016141645A (enExample) |
| WO (3) | WO2015143652A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105418615B (zh) * | 2015-12-09 | 2018-02-02 | 北京工业大学 | 苯甲酰胺衍生物及制备和应用 |
| US11701345B2 (en) | 2017-06-19 | 2023-07-18 | University Of Maryland, Baltimore | Car activator agents for cyclophosphamide-based treatments of cancer |
| WO2019070943A1 (en) | 2017-10-04 | 2019-04-11 | Dana-Farber Cancer Institute, Inc. | SMALL MOLECULE INHIBITION OF SALL4 TRANSCRIPTION FACTOR AND USES THEREOF |
| JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
| DK3724191T3 (da) * | 2017-12-15 | 2022-03-14 | Pyramid Biosciences Inc | 5-(2-(2,5-difluorphenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazol[1,5-a]pyrimidinderivater og lignende forbindelser som trk-kinasehæmmere til cancerbehandling |
| ES2965494T3 (es) | 2018-04-12 | 2024-04-15 | Bayer Ag | Derivados de N-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1H-1,2,4-triazol-5-il]etil}benzamida y los correspondientes derivados de piridina-carboxamida como plaguicidas |
| KR102129114B1 (ko) | 2018-07-26 | 2020-07-02 | 주식회사 온코파마텍 | TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물 |
| EP3841098B1 (en) | 2018-08-22 | 2026-01-14 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (trk) degradation compounds and methods of use |
| US11969472B2 (en) | 2018-08-22 | 2024-04-30 | Cullgen (Shanghai), Inc. | Tropomyosin receptor kinase (TRK) degradation compounds and methods of use |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| CN111269233A (zh) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
| CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
| BR112022006791A2 (pt) | 2019-10-09 | 2022-06-28 | Bayer Ag | Novos compostos heteroaril-triazol como pesticidas |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| TW202134226A (zh) | 2019-11-18 | 2021-09-16 | 德商拜耳廠股份有限公司 | 作為殺蟲劑之新穎雜芳基-三唑化合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| BR112022016901A2 (pt) | 2020-02-26 | 2022-12-06 | Cullgen Shanghai Inc | Compostos de degradação do receptor de tropomiosina quinase (trk) e métodos de uso |
| CN115916771B (zh) * | 2020-04-02 | 2025-04-01 | 浙江华海药业股份有限公司 | 多靶点的抗肿瘤化合物及其制备方法和应用 |
| AR122141A1 (es) * | 2020-05-28 | 2022-08-17 | Lilly Co Eli | Inhibidor de trka |
| CN113666862B (zh) * | 2021-08-18 | 2024-05-31 | 山东大学 | 一种通过镍催化不对称硝化反应制备手性3-硝基吲哚类化合物的方法 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB599834A (en) * | 1943-04-08 | 1948-03-22 | Francolor Sa | Improvements in or relating to the manufacture of azodyestuffs |
| EP0714898B1 (en) * | 1994-06-21 | 2001-11-14 | Otsuka Pharmaceutical Factory, Inc. | PYRAZOLO [1,5-a]PYRIMIDINE DERIVATIVE |
| IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
| DE19946322A1 (de) | 1999-09-28 | 2001-03-29 | Bayer Ag | Verfahren zur Konditionierung von Ionenaustauscherharzen |
| FR2807660A1 (fr) | 2000-04-13 | 2001-10-19 | Warner Lambert Co | Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques |
| WO2001081345A1 (en) * | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Aromatic amide compounds |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20050009876A1 (en) * | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
| KR100713137B1 (ko) * | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
| PL368347A1 (en) * | 2001-09-26 | 2005-03-21 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| US20030144518A1 (en) * | 2001-12-07 | 2003-07-31 | The Procter & Gamble Company | Process for preparing 3-acylamino-imidazo[1,2-a]pyridines |
| JP2003231687A (ja) * | 2002-02-04 | 2003-08-19 | Japan Tobacco Inc | ピラゾリル縮合環化合物及びその医薬用途 |
| AU2003245700A1 (en) * | 2002-02-12 | 2003-09-04 | Glaxo Group Limited | Pyrazolopyridine derivatives |
| US7098334B2 (en) * | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| EP1388341A1 (en) | 2002-08-07 | 2004-02-11 | Aventis Pharma Deutschland GmbH | Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| KR101410692B1 (ko) | 2002-12-24 | 2014-06-24 | 리나트 뉴로사이언스 코프. | 항-ｎｇｆ 항체 및 그것을 이용하는 방법 |
| CA2524321A1 (en) | 2003-05-01 | 2004-11-18 | Bristol-Myers Squibb Company | Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors |
| TWI385180B (zh) | 2003-07-15 | 2013-02-11 | 安美基公司 | 作為選擇性神經生長因子（ｎｇｆ）通道抑制劑之人類抗-ｎｇｆ中和抗體 |
| EP1667983A4 (en) | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| US20050143384A1 (en) | 2003-10-30 | 2005-06-30 | Eric Sartori | Amide thiadiazole inhibitors of plasminogen activator inhibitor-1 |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| US20070185152A1 (en) * | 2004-03-02 | 2007-08-09 | Smithkline Beecham Corporation | Inhibitors of akt activity |
| MXPA06012394A (es) | 2004-04-30 | 2007-01-31 | Bayer Pharmaceuticals Corp | Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer. |
| AU2006215394B2 (en) | 2005-02-16 | 2009-10-08 | Astrazeneca Ab | Chemical compounds |
| CN101208093A (zh) | 2005-04-27 | 2008-06-25 | 阿斯利康(瑞典)有限公司 | 吡唑-嘧啶衍生物在治疗疼痛中的用途 |
| AU2006248780B2 (en) | 2005-05-16 | 2010-06-03 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| ITRM20050332A1 (it) | 2005-06-24 | 2006-12-25 | Lay Line Genomics Spa | Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore. |
| CA2615105A1 (en) * | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| JP2009502734A (ja) | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| CN101287707A (zh) | 2005-10-13 | 2008-10-15 | 德福根有限公司 | 激酶抑制剂 |
| JP2009519208A (ja) | 2005-12-15 | 2009-05-14 | 塩野義製薬株式会社 | アミド誘導体を含有する医薬組成物 |
| MX2008015457A (es) | 2006-07-07 | 2009-01-16 | Boehringer Ingelheim Int | Derivados de heteroaril substituido en fenil y el uso de los mismos como agentes anti-tumorales. |
| JPWO2008016131A1 (ja) * | 2006-08-04 | 2009-12-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| BRPI0718266A2 (pt) | 2006-10-30 | 2014-01-07 | Novartis Ag | Compostos heterocíclicos como agentes anti-inflamatórios. |
| NZ580457A (en) | 2007-04-06 | 2012-03-30 | Neurocrine Biosciences Inc | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| GB0708188D0 (en) * | 2007-04-27 | 2007-06-06 | Merck Sharp & Dohme | Therapeutic compounds |
| WO2008154241A1 (en) * | 2007-06-08 | 2008-12-18 | Abbott Laboratories | 5-heteroaryl substituted indazoles as kinase inhibitors |
| EP2176249A2 (en) | 2007-07-02 | 2010-04-21 | Boehringer Ingelheim International GmbH | New chemical compounds |
| CL2008001943A1 (es) | 2007-07-02 | 2009-09-11 | Boehringer Ingelheim Int | Compuestos derivados de fenil-triazol, inhibidores de enzimas de señales especificas que participan del control de la proliferacion celular; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer, infecciones, enfermedades inflamatorias y autoinmunes. |
| CA2693901C (en) * | 2007-07-20 | 2015-12-29 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| MX2010003760A (es) | 2007-10-09 | 2010-04-21 | Merck Patent Gmbh | Derivados de n-(pirazol-3-il)-benzamida como activadores de glucocinasa. |
| SI2350075T1 (sl) | 2008-09-22 | 2014-06-30 | Array Biopharma, Inc. | Substituirane imidazo (1,2b)piridazinske spojine kot Trk kinazni inhibitorji |
| US8703962B2 (en) | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
| KR101048448B1 (ko) * | 2008-11-21 | 2011-07-11 | 한국화학연구원 | 신규 피라졸로[4,3-ｂ]피리딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| EP2376495A4 (en) | 2008-12-08 | 2012-10-31 | Vm Pharma Llc | COMPOSITIONS OF PROTEIN RECEPTOR TYROSINE KINASE INHIBITORS |
| US20120065247A1 (en) | 2009-03-27 | 2012-03-15 | Discoverybiomed, Inc. | Modulating ires-mediated translation |
| WO2011014775A1 (en) * | 2009-07-31 | 2011-02-03 | The Brigham And Women's Hospital, Inc. | Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses |
| BR112012010752B1 (pt) * | 2009-11-05 | 2021-07-20 | University Of Notre Dame Du Lac | Compostos imidazo[1,2-a]piridina |
| KR101759759B1 (ko) | 2010-07-02 | 2017-07-19 | 길리애드 사이언시즈, 인코포레이티드 | 세포자멸사 신호-조절 키나아제 저해제 |
| SG10201505997TA (en) * | 2010-08-05 | 2015-09-29 | Amgen Inc | Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase |
| JP5805767B2 (ja) | 2010-09-01 | 2015-11-10 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ | Ｎ−（テトラゾール−５−イル）アリールカルボキサミド類及びｎ−（トリアゾール−５−イル）アリールカルボキサミド類並びに除草剤としてのそれらの使用 |
| KR20130141500A (ko) * | 2010-09-29 | 2013-12-26 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
| US9079859B2 (en) | 2011-01-21 | 2015-07-14 | Auckland Uniservices Limited | Synthetic lethal targeting of glucose transport |
| KR20140051835A (ko) | 2011-02-09 | 2014-05-02 | 신젠타 파티서페이션즈 아게 | 살곤충 화합물 |
| RS55582B1 (sr) | 2011-05-13 | 2017-06-30 | Array Biopharma Inc | Jedinjenja pirolidinil uree, pirolidinil tiouree i pirolidinil guanidina kao inhibitori trka kinaze |
| CN102796103A (zh) | 2011-05-23 | 2012-11-28 | 南京英派药业有限公司 | 6-（芳基甲酰）咪唑并[1,2-a]嘧啶和6-（芳基甲酰）[1,2,4]三唑并[4,3-a]嘧啶作为Hedgehog抑制剂及其应用 |
| DK2714668T3 (en) | 2011-05-23 | 2017-03-20 | Merck Patent Gmbh | thiazole |
| US9102673B2 (en) * | 2011-07-12 | 2015-08-11 | Merck Sharp & Dohme Corp. | Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors |
| AU2012339753A1 (en) * | 2011-11-14 | 2014-06-19 | Tesaro, Inc. | Modulating certain tyrosine kinases |
| CN104114553B (zh) * | 2011-12-12 | 2017-03-01 | 雷迪博士实验室有限公司 | 作为原肌球蛋白受体激酶(Trk)抑制剂的取代的吡唑并[1,5‑a]吡啶 |
| EP2689779A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| EP2689778A1 (en) * | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| TWI652014B (zh) * | 2013-09-13 | 2019-03-01 | 美商艾佛艾姆希公司 | 雜環取代之雙環唑殺蟲劑 |
-
2014
- 2014-03-26 WO PCT/CN2014/074143 patent/WO2015143652A1/en not_active Ceased
-
2015
- 2015-03-23 MX MX2016012483A patent/MX2016012483A/es unknown
- 2015-03-23 KR KR1020167029495A patent/KR20160132114A/ko not_active Withdrawn
- 2015-03-23 WO PCT/US2015/021952 patent/WO2015148354A2/en not_active Ceased
- 2015-03-23 CA CA2942817A patent/CA2942817A1/en not_active Abandoned
- 2015-03-23 US US15/129,206 patent/US9862716B2/en active Active
- 2015-03-23 JP JP2016558339A patent/JP2017508766A/ja active Pending
- 2015-03-23 CA CA2942957A patent/CA2942957A1/en not_active Abandoned
- 2015-03-23 EP EP15769224.5A patent/EP3122345B1/en active Active
- 2015-03-23 KR KR1020167029497A patent/KR20160131119A/ko not_active Withdrawn
- 2015-03-23 CN CN201580027484.1A patent/CN106456582A/zh active Pending
- 2015-03-23 AU AU2015236438A patent/AU2015236438A1/en not_active Abandoned
- 2015-03-23 MX MX2016012481A patent/MX2016012481A/es unknown
- 2015-03-23 JP JP2016558347A patent/JP2017512786A/ja active Pending
- 2015-03-23 WO PCT/US2015/022004 patent/WO2015148373A2/en not_active Ceased
- 2015-03-23 CN CN201580027483.7A patent/CN106456581A/zh active Pending
- 2015-03-23 RU RU2016141645A patent/RU2016141645A/ru not_active Application Discontinuation
- 2015-03-23 EP EP15769051.2A patent/EP3122344B1/en active Active
- 2015-03-23 RU RU2016141647A patent/RU2016141647A/ru not_active Application Discontinuation
- 2015-03-23 US US15/128,793 patent/US9862707B2/en active Active
- 2015-03-23 AU AU2015236363A patent/AU2015236363A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512786A5 (enExample) | ||
| RU2016141647A (ru) | ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ | |
| JP2017508766A5 (enExample) | ||
| JP2017512794A5 (enExample) | ||
| JP2018519323A5 (enExample) | ||
| JP5140600B2 (ja) | オーロラキナーゼのアザインドール阻害薬 | |
| JP2007519694A5 (enExample) | ||
| RU2016141646A (ru) | Ингибиторы trka киназы, основанные на них композиции и способы | |
| JP2016517417A5 (enExample) | ||
| JP2009524670A5 (enExample) | ||
| JP2016526576A5 (enExample) | ||
| KR20150132384A (ko) | 항암 및 항-증식 활성을 나타내는 n-아실-n''-(피리딘-2-일) 우레아 및 유사체 | |
| JP2017501234A5 (enExample) | ||
| JP2016523911A5 (enExample) | ||
| JP2009510161A5 (enExample) | ||
| JP2017537948A5 (enExample) | ||
| JP2016519685A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2012532931A5 (enExample) | ||
| JP2014531449A5 (enExample) | ||
| JP2018503673A5 (enExample) | ||
| JP2017526622A (ja) | ３−アミノ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 | |
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2017523223A5 (enExample) | ||
| JP2020502230A5 (enExample) |